---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-037060"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2025-10-02T23:59:59+00:00"
generated_at: "2026-05-17T04:54:18.243815+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q1 FY2026: Med Tech sales up 26.1%; raises full-year guidance

## Summary
- Net sales $75.7M (+12.2% YoY pro forma); GAAP loss $0.26/sh, adj loss $0.10/sh.
- Med Tech segment $35.3M (+26.1%): Auryon +20.1%, thrombectomy +41.2%, NanoKnife +26.7%.
- Adjusted EBITDA $2.2M vs ($0.2M) prior year; cash $38.8M, debt-free.
- Raised FY2026 guidance: net sales $308-$313M, adj EBITDA $6-$10M, adj EPS ($0.33)-($0.23).
- Enrolled first patients in AMBITION BTK and RECOVER-AV trials; PRESERVE study published.

## SEC filing metadata
- accession: 0001140361-25-037060
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2025-10-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036125037060/0001140361-25-037060-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036125037060/ef20056554_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-037060
- JSON: https://secwatch.observer/filing/0001140361-25-037060.json
- Plain text: https://secwatch.observer/filing/0001140361-25-037060.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.